



PRESS RELEASE

Published: 26-10-2017

Inhalation Sciences: AstraZeneca report finds Preciselnhale 'reduces the risk' of failure when developing inhaled drugs

STOCKHOLM, SWEDEN, – 26 October, 2017. New research released by Astra Zeneca at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27 shows that Preciselnhale can reduce risk and speed up drug development: “dose levels could be selected with confidence before moving into the toxicology study, reducing the risk...inherent with this class of drugs.”

The report found that Inhalation Sciences' labtech system Preciselnhale delivered results that make it safer and quicker for scientists to choose which candidate drugs to continue developing: “Using this data, dose levels could be selected with confidence before moving into the toxicology study, reducing the risk for tolerability limitations inherent with this class of drugs.”

The report concluded: “it was demonstrated that the Preciselnhale was precise enough to perform this investigation and offers a unique possibility in further exploring inhaled dosing... removing some of the possible variance in other exposure systems.”

The findings are in a poster titled 'Inhaled Particle Size evaluation on PK Profile using the Preciselnhale', released at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27.

ISAB's CSO Per Gerde, inventor of Preciselnhale: “We're proud Astra Zeneca achieved such positive results. This is clear evidence that the precision and consistency of the data Preciselnhale delivers can save time and reduce costs and risks for the pharma industry when developing drugs to be inhaled.”

For more information about Inhalation Sciences please contact:

Fredrik Sjövall, CEO
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company's patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on October 26, 2017.